Delivery Order SPE2DR25D9227-SPE2DR26FFLP1
- Not listed
- The Defense Logistics Agency awarded a $2,493.75 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for FASENRA (benralizumab) 30 mg/mL pens. The award was issued on January 6, 2026, with an ultimate completion date of January 7, 2026, and carries no set-aside designation. This delivery order represents a routine procurement under DMS Pharmaceutical Group's broader Pharmaceutical Prime Vendor...
- The Defense Logistics Agency (DLA) issued a delivery order valued at $2,493.75 to DMS Pharmaceutical Group Inc. for FASENRA Pen 30 mg/mL, a biologic pharmaceutical product. Awarded on January 8, 2026, this firm fixed-price delivery order is issued without set-aside designation and reflects DMS Pharmaceutical Group's competitive capability in unrestricted federal procurement. The place of performance is Park Ridge, Illinois, with an ultimate completion date of January 9, 2026. This delivery order...
- The Defense Logistics Agency issued a delivery order valued at $14,962.50 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of FASENRA PEN 30 MG/ML. This firm fixed-price delivery order, awarded on January 5, 2026, with an ultimate completion date of January 6, 2026, was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award...
- The Defense Logistics Agency awarded a delivery order valued at $7,481.25 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for FASENRA (benralizumab) pen 30 mg/mL. This firm fixed-price delivery order, issued on January 7, 2026, with an ultimate completion date of January 8, 2026, was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award...
- The Defense Logistics Agency awarded a $9,975 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for Fasenra Pen 30 mg/ml on January 7, 2026. This delivery order, which carries no set-aside designation, is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $12,468.75 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for FASENRA 30 mg/ml syringes. The contract, issued on November 7, 2025, with an ultimate completion date of November 10, 2025, carries no set-aside designation, indicating the awardee competed in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical...
- The Defense Logistics Agency awarded a $2,275.00 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for FASENRA Pen 30 mg/ml. The delivery order, which became effective on September 5, 2025, with an ultimate completion date of September 26, 2025, will be performed in Conshohocken, Pennsylvania. This award was made without a set-aside designation, allowing the contractor to compete directly in the...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $2,275.00 to DMS Pharmaceutical Group Inc. for FASENRA PEN 30 MG/ML, a pharmaceutical product used in the treatment of severe asthma. The award was issued on August 5, 2025, with an ultimate completion date of August 26, 2025, with performance taking place in Conshohocken, Pennsylvania. This delivery order does not utilize any set-aside designation and represents a single transaction under DMS Pharmaceutical Group's...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valued at $4,887.00, is for the supply of FASENRA PEN 30 MG/MLML, a pharmaceutical product. This delivery order is under a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group that has a ceiling value of up to $499,999,999 and runs through December 31, 2025. The IDC allows DLA to...
- The Defense Logistics Agency issued a firm fixed-price delivery order valued at $4,987.52 to DMS Pharmaceutical Group Inc. for Fasenra Pen 30mg/ml, an injectable pharmaceutical product used in respiratory and immunological treatments. This delivery order, awarded on December 2, 2025, with an ultimate completion date of the same day, carries no set-aside designation and will be performed in Park Ridge, Illinois. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical...
- SPE2DR25D9227Indefinite Delivery Contract
- SPE2DR25D9227-SPE2DR26FFLP1Delivery Order
The Defense Logistics Agency issued a delivery order valued at $2,493.75 to DMS Pharmaceutical Group Inc. for FASENRA Pen 30 mg/ml on January 8, 2026, with an ultimate completion date of January 9, 2026. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was awarded this firm fixed-price delivery order without a set-aside designation. The award represents one of numerous delivery orders issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to supply pharmaceutical products to military healthcare facilities worldwide. The PPV-G GEN V contract, awarded to DMS Pharmaceutical Group on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. Under this vehicle, the company supplies a comprehensive range of pharmaceutical products including branded and generic prescription medications, biologics, vaccines, and medical consumables to support Department of Defense healthcare operations globally. FASENRA (benralizumab) is a specialty biologic used in asthma treatment, consistent with DMS Pharmaceutical Group's established portfolio of high-value specialty pharmaceuticals and biologics serving the federal military medical system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.5k | 1/7/26 |